



Biotech Capital (BTC) - ASX Announcement

4 July 2016

## Biotech Capital invests in bio101Group

Biotech Capital Limited (ASX: BTC) announced today that it has made an initial investment in a wholly owned investee company; bio101Group Pty Ltd ([www.bio101.com](http://www.bio101.com)).

This latest investment is consistent with Biotech Capital's strategy of growing its service offering to local and international companies in the biotechnology, medical device and pharmaceutical industry. This further extends the range of services currently being provided following the acquisition of Sydney-based advisory firm Biointellect in April.

With its team of experienced Chartered Accountants, **bio101** provides a range of finance and administration services to private, public and listed companies in the Australian life sciences sector. These services include accounting, company secretarial, taxation, grant applications, payroll administration, business development, royalty and partner management.

Biotech Capital's Chairman Richard Treagus commented, "**bio101** has been established in response to the growing demand for a simple and fully integrated finance and administration service for start-up companies in the life science sector. Our clients are now able to access the full range of services, industry network and resources of the Biotech Capital group and in so doing we expect this will further assist them in successfully growing their businesses."

### About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The company has the longer-term objective of building a group of complimentary businesses that are entrepreneurial, innovative, globally focused and when operating together have the ability to generate better health outcomes and value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares.



Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

*Forward-looking Statements*

*This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.*

**For more information, please contact:**

Dr. Richard Treagus, Chairman  
[rtreagus@biotechcapital.com.au](mailto:rtreagus@biotechcapital.com.au) +61 417 520 509